不可切除Ⅲ期EGFR突变阳性肺腺癌生存预后因素:CCRT前PET-CT的影响
本研究评估同步放化疗(CCRT)前PET-CT分期对不可切除Ⅲ期EGFR突变阳性肺腺癌患者生存的影响。
要点
- CCRT前PET-CT分期与不可切除Ⅲ期EGFR突变阳性肺腺癌生存改善相关(校正HR 0.74)。
- 独立预后因素包括性别、年龄、临床分期、辅助治疗、吸烟状态、合并症指数及治疗设置。
- 该研究支持在CCRT前对这类患者进行PET-CT分期以评估预后。
核心结论
- 对于不可切除的临床ⅢA-ⅢC期EGFR突变阳性肺腺癌患者,CCRT前PET-CT分期与生存改善相关。
- 研究还识别出多个独立预后因素,包括男性、年龄分组、临床分期、辅助治疗、吸烟状态、Charlson合并症指数评分及治疗设置。
研究设计与样本
- 研究纳入接受根治性CCRT的不可切除ⅢA-ⅢC期EGFR突变阳性肺腺癌患者,分为CCRT前接受PET-CT分期组与其他分期方法组。
主要发现
- PET-CT分期与生存改善相关,校正全因死亡HR为0.74(95%CI 0.71-0.79)。
- 其他预后因素包括男性、年龄分组、临床分期、辅助治疗、吸烟状态、Charlson合并症指数评分及治疗设置。
关键数值与推荐
- PET-CT分期组校正全因死亡HR 0.74(95%CI 0.71-0.79)。
临床怎么用
- 对不可切除Ⅲ期EGFR突变阳性肺腺癌患者,CCRT前可考虑PET-CT分期以辅助预后评估。
- 临床可结合男性、年龄、临床分期、辅助治疗、吸烟状态、Charlson合并症指数及治疗设置等预后因素进行综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the survival impact of pre-concurrent chemoradiotherapy (CCRT) staging with positron emission tomography-CT (PET-CT) in patients with unresectable epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma. METHODS: Patients with unresectable stage IIIA-IIIC EGFR mutation-positive adenocarcinoma undergoing definitive CCRT were divided into two groups: those who received PET-CT staging prior to CCRT and those with other staging methods. Survival outcomes were compared after propensity score matching. RESULTS: Analysis of 11 856 patients (5928 in each group) showed that PET-CT staging was associated with improved survival (adjusted HR of all-cause mortality: 0.74, 95% CI 0.71 to 0.79). Other prognostic factors included male sex, age group, clinical stage, adjuvant treatment, smoking status, Charlson Comorbidity Index score and treatment setting. CONCLUSION: Pre-CCRT staging with PET-CT in patients with unresectable EGFR mutation-positive adenocarcinoma of clinical stage IIIA-IIIC was associated with enhanced survival. Independent prognostic factors were also identified.
引用
- Lin WC, Chen WM, Shia BC, et al. Prognostic factors for survival in unresectable stage III EGFR mutation-positive lung adenocarcinoma: impact of pre-CCRT PET-CT. Thorax. 2024. PMID: 38331580. doi:10.1136/thorax-2023-220702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。